Barriers of Access to Breast Reconstruction Barriers of Access to Breast Reconstruction

Are all breast cancer patients offered the option of breast reconstruction? What strategies may help improve access to care?Plastic and Reconstructive Surgery
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Plastic Surgery & Aesthetic Medicine Journal Article Source Type: news

Related Links:

ConclusionsCollectively, our results provide evidence for a novel mechanism by which ERβ exerts oncosuppressive effect in AR-positive TBNC through direct and indirect interactions with AR. Moreover, ERβ expression may identify a new subset of TNBC that would respond more favorable to anti-androgens.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
ConclusionUTMD can improve Endostar delivery in the targeting tumor tissue and mediate synergistic antiangiogenetic and antitumor effects, which may be a potential therapeutic strategy for refractory breast cancer.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
AbstractPurposeThe prevalence and clinical relevance ofTP53 andPIK3CA mutations in pretreatment breast cancer have been previously reported. However, little is known regarding these mutations in residual tumor tissues after neoadjuvant chemotherapy. Here, we investigated the association betweenTP53 andPIK3CA mutations in residual disease and survival of breast cancers.MethodsTP53 andPIK3CA somatic mutations were examined in 353 post-neoadjuvant chemotherapy residual tumor tissues by Sanger sequencing. Survival curves of patients withTP53 andPIK3CA mutations were compared using the Kaplan –Meier method.ResultsFifty-si...
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 23 April 2019Source: Materials Science and Engineering: CAuthor(s): Mariadhas Valan Arasu, A. Madankumar, J. Theerthagiri, Sunitha Salla, S. Prabu, Hyun-Seok Kim, Naif Abdullah Al-Dhabi, Selvaraj Arokiyaraj, Veeramuthu DuraipandiyanAbstractZnO nanoparticles with flakes-like structures were synthesized by simple wet chemical route using triethanolamine as a mild base. The well distributed ZnO nanoflakes onto carbon nanoplates (ZnO/C) were prepared by wet impregnation method. The crystalline structure and purity of the synthesized samples was inspected using XRD. The shape, structural morph...
Source: Materials Science and Engineering: C - Category: Materials Science Source Type: research
Conclusions: Formononetin enhances the tumoricidal effect of everolimus by inhibiting the activity of Akt. PMID: 31007702 [PubMed]
Source: Evidence-based Complementary and Alternative Medicine - Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research
In conclusion, this protein can be used for animal immunization toward preparation of a new monoclonal antibody that can be introduced as a drug in the treatment of breast cancer. PMID: 31009334 [PubMed - in process]
Source: Monoclonal Antibodies in Immunodiagnosis and Immunotherapy - Category: Microbiology Tags: Monoclon Antib Immunodiagn Immunother Source Type: research
This study provides insight into the experiences of young women living with advanced breast cancer. Because these women may not appear ill to the general population, their needs and struggles are not well understood. The results of this study can be a baseline for additional research and clinical interventions. PMID: 31007263 [PubMed - in process]
Source: Oncology Nursing Forum - Category: Nursing Authors: Tags: Oncol Nurs Forum Source Type: research
Triple-negative breast cancer (TNBC) tumors with estrogen receptor-beta and a mutated p53 tumor suppressor might be responsive to tamoxifen, a series of preclinical studies suggests.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
(Georgetown University Medical Center) A new study suggests that Oncotype DX-guided treatment could reduce the cost for the first year of breast cancer care in the US by about $50 million (about 2 percent of the overall costs in the first year). The study by Georgetown Lombardi Comprehensive Cancer Center and National Cancer Institute researchers was published April 24, in JNCI.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Date: Wednesday, 05 15, 2019; Speaker: Lucile Adams-Campbell, Ph.D., Professor of Oncology, Georgetown University; 10; Masur Auditorium ; CME Credit; Videocast Event
Source: NIH Calendar of Events - Category: American Health Source Type: events
More News: Breast Cancer | Cancer | Cancer & Oncology | Health | Plastic Surgery